Script Sermorelin

Citation register / full list

Sermorelin References: The GHRH(1-29) Literature, Cited in Full

Every quantitative claim on this site resolves to one of these sources. DOIs and PubMed identifiers are listed for verification.

Back to the researchRead the FAQ

How to read this list

Each numbered entry corresponds to the inline [N] markers across the site. Where a study reported a quantitative result — a height velocity, a half-life, an IGF-1 percentage — the citation here is the source of that figure. Entries carry a DOI, a PubMed identifier (PMID), or an FDA URL so any claim can be traced. The list spans the foundational pharmacokinetic and pediatric work of the 1990s, the aging and cognition trials, the preclinical neuro literature, and recent 2024-2026 reviews and regulatory references.

  1. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. ↗
  2. Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. ↗
  3. Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. ↗
  4. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. ↗
  5. Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. ↗
  6. Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. NCT00257712. ↗
  7. Jaszberenyi M, Rick FG, et al. Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease. Aging (Albany NY). 2012;4(11):755-67. ↗
  8. Telegdy G, Tanaka M, Schally AV. Effects of the growth hormone-releasing hormone (GH-RH) antagonist on brain functions in mice. Behav Brain Res. 2011;224(1):155-8. ↗
  9. Sáez JM. Possible usefulness of growth hormone/insulin-like growth factor-I axis in Alzheimer's disease treatment. Endocr Metab Immune Disord Drug Targets. 2012;12(3):274-86. ↗
  10. Lee H, et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003;55(10):1369-1377. ↗
  11. Muller EE, Locatelli V, Cocchi D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. ↗
  12. Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  13. Datta A, Ghosh B, et al. Mesenchymal stem cell therapy with GHRH receptor analog resolves post-stroke vasogenic edema via modulating AQP4 and mitochondria-ER crosstalk. J Transl Med. 2026;24. ↗
  14. Villar-Gouy KR, Salmon CEG, et al. Brain morphometry and estimation of aging brain in subjects with congenital untreated isolated GH deficiency. J Endocrinol Invest. 2024;47:2797-2807. ↗
  15. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA.gov; 2025. ↗